文献速递淋巴瘤

基线循环肿瘤DNA与总代谢肿瘤体积作为侵袭性大B细胞淋巴瘤早期结局预测指标:一项真实世界112例患者队列研究

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.
PubMed 文献 · Br J Haematol · 2023-04-10

该单中心观察性研究纳入112例新诊断大B细胞淋巴瘤(LBCL)患者,接受R-CHOP/R-CHOP样化疗,评估循环肿瘤DNA(ctDNA)负荷与总代谢肿瘤体积(TMTV)联合的预后价值。95例可检测到ctDNA,中位浓度3.15 log hGE/mL;102例有TMTV测量,中位值501 mL。高ctDNA负荷(>3.57 log hGE/mL)或高TMTV(>200 mL)均与更短的1年无进展生存(PFS)相关,两者联合可识别三个预后组,双高组PFS最短。

要点

  • 高ctDNA负荷(>3.57 log hGE/mL)与更短1年PFS相关(44% vs 83%,p<0.001)。
  • 高TMTV(>200 mL)与更短1年PFS相关(64% vs 97%,p=0.002)。
  • ctDNA与TMTV双高组PFS最短(p<0.001),联合可改善风险分层。

核心结论

  • 即使随访时间短,基线ctDNA负荷联合TMTV可改善侵袭性LBCL患者的风险分层。
  • 作者认为,在不久的将来,极高危患者一线治疗可能受益于CAR T细胞疗法或双特异性抗体。

研究设计与样本

  • 观察性单中心研究,纳入112例新诊断LBCL患者,接受R-CHOP/R-CHOP样化疗。
  • ctDNA负荷通过靶向40基因淋巴panel对游离DNA(cfDNA)行下一代测序后计算。
  • TMTV采用基于人工智能的全自动淋巴瘤病灶分割方法测量。

主要发现

  • 95例患者cfDNA样本可检测到ctDNA,中位浓度3.15 log haploid genome equivalents每mL。
  • 102例患者有TMTV测量值,中位TMTV为501 mL。
  • 高ctDNA负荷(>3.57 log hGE/mL)与更短1年PFS相关(44% vs 83%,p<0.001)。
  • 高TMTV(>200 mL)与更短1年PFS相关(64% vs 97%,p=0.002)。
  • ctDNA与TMTV联合识别出三个预后组,双高组PFS最短(p<0.001)。

关键数值与推荐

  • ctDNA高负荷阈值:>3.57 log hGE/mL。
  • TMTV高阈值:>200 mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 20%-50% of patients with large B-cell lymphoma (LBCL) experience poor outcomes. We aimed to evaluate the combined prognostic value of circulating tumour DNA (ctDNA) and total metabolic tumour volume (TMTV) in LBCL. This observational single-centre study included 112 newly diagnosed LBCL patients, receiving R-CHOP/R-CHOP-like chemotherapies. CtDNA load was calculated following next-generation sequencing of cell-free DNA (cfDNA) using a targeted 40-gene lymphopanel. TMTV was measured using a fully automated artificial intelligence-based method for lymphoma lesion segmentation. CtDNA was detected in cfDNA samples from 95 patients with a median concentration of 3.15 log haploid genome equivalents per mL. TMTV measurements were available for 102 patients. The median TMTV was 501 mL. High ctDNA load (>3.57 log hGE/mL) or high TMTV (>200 mL) were associated with shorter 1-year PFS (44% vs. 83%, p < 0.001 and 64% vs. 97%, p = 0.002, respectively). When combined, three prognostic groups were identified. The shortest PFS was observed when both TMTV and ctDNA load were high (p < 0.001). Even with a short follow up, combining ctDNA load with TMTV improved the risk stratification of patients with aggressive LBCL. In the near future, very high-risk patients could benefit from CAR T-cell therapy or bispecific antibodies as first-line treatments.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Le Goff E, Blanc-Durand P, Roulin L, et al. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. Br J Haematol. 2023. PMID: 37038217. doi:10.1111/bjh.18809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。